Drug Type CRISPR/Cas9, AAV based gene therapy |
Synonyms Autologous CD34+ cells edited with CRISPR/Cas9 and transduced with an adeno-associated virus vector serotype 6 containing the codon-optimized version of PKLR gene, CG001 (DanausGT) + [2] |
Target |
Mechanism PKLR modulators(Pyruvate kinase isozymes R/L modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (EU) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pyruvate Kinase Deficiency | Phase 1 | CN | 04 Aug 2023 |